Not only are there more dollars being place in value-based contracts, but the healthcare community is starting to see the benefits of these programs, explained Scott Hewitt, vice president, payment strategy and innovation, UnitedHealthcare.
Not only are there more dollars being place in value-based contracts, but the healthcare community is starting to see the benefits of these programs, explained Scott Hewitt, vice president, payment strategy and innovation, UnitedHealthcare.
Transcript
What has been physician interest in participating in value-based contracts? Are you seeing some skepticism disappear?
One of the things that we’ve been doing, as I’m sure most payers are, is tracking what is our evolution in terms of moving to value-based contracting. In 2012, when United Healthcare first started tracking this information, we had roughly $12 billion in spend tied to value-based contracts. Now 5 years later, 6 years later, we have almost $70 billion tied to value-based contracts and not only do we have more dollars tied to value-based contracts, we’re seeing the evolution move form a preponderance of performance-based contracts—so metrics-specific programs—to more programs that are more focused on bundled payments and population health.
So, I think that the provider community, the entire healthcare landscape, is changing to the point where we are seeing the benefits of these programs. Certainly, with the actions that CMS is taking, actions that UnitedHealthcare is taking, actions that employers and states are asking of UnitedHealthcare to undertake. This is the direction that people want to move, and it’s the direction that people should be moving. I mean there’s no other industry where we simply increase reimbursement to somebody—you and I as employees don’t just automatically get a rate increase or our salaries don’t go up on an annual if we’re not performing at a higher level, right, as an example.
We need to bring in more components where we look at the cost and quality of healthcare and how is it being delivery, how is it being received by the members? Is it making a difference? So, I understand the question in terms of providers saying, “I’ve got all these different programs, all these different metrics that I’m being asked to look at. Is it actually resulting in a benefit for the consumer?” And I would think—I know—that the data at UnitedHealthcare shows that it is.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More